BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LAE103 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LAE103\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07230496-11048@assetmemo.bio
DTSTAMP:20261121T005415Z
DTSTART;VALUE=DATE:20280320
DTEND;VALUE=DATE:20280321
SUMMARY:LAE103: Phase 1 readout est. (NCT07230496)
DESCRIPTION:LAE103\, phase 1\, Obesity.\nStudy: A Study to Investigate Safe
 ty\, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination 
 With LAE102 in Healthy Overweight/Obese Participants\nEstimated primary co
 mpletion: 20 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lae103#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07230496
URL:https://assetmemo.bio/drug/lae103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
